ASTRO: Angiostatin May Enhance Radiation's Effects Against Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ASTRO: Angiostatin May Enhance Radiation's Effects Against Cancer

By Koren Capozza
Special to DG News

SAN FRANCISCO, CA -- November 8, 2001 -- The results of the first clinical trial to test radiation therapy with the new cancer drug, angiostatin, indicate the combination is safe and has few side effects.

The finding was presented today at the American Society of Therapeutic Radiology and Oncology (ASTRO), in San Francisco, California.

Angiostatin is one of a new promising class of drugs that were designed to halt the growth of blood vessels that feed cancerous tumors by cutting off the supply of blood to the tumor.

Researchers from Jefferson Medical College administered angiostatin intravenously to 15 patients five times per week for up to seven weeks. The subjects all had tumors associated with head and neck, thoracic, or pelvic region cancers and were between the ages of 35 and 70 years. They were treated at Thomas Jefferson University in Philadelphia.

The drug was given one hour prior to radiation therapy.

The Phase I clinical trial was designed to determine the safety of the drug for future widespread use on cancer patients.

The team of researchers found that the patients suffered no significant side effects and all had a partial or complete response to the radiation and drug treatment. They concluded that a daily 10-minute infusion of 15 mg/m2 the drug is a safe dose for a variety of cancer patients.

"It was important to demonstrate that this drug would be safe and set the stage for a phase II trial, where we use radiotherapy, chemotherapy and angiostatin," said co-author Adam Dicker, MD, assistant professor of radiation oncology at Jefferson Medical College. Dr. Dicker led the study with Walter Curran, Jr., MD, chair of radiation oncology at Jefferson.

Previous studies have shown that angiostatin is safe for clinical use, but this study was the first to examine how the drug interacts with radiation therapy.

"There will be a lot of research in this area - it’s an exciting time," Dr. Dicker said.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities